|Preclinical evaluation of caprylic acid-fractionated IgG antivenom for the treatment of Taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea.|
|Jump to Full Text|
|PMID: 21610854 Owner: NLM Status: MEDLINE|
|BACKGROUND: Snake bite is a common medical emergency in Papua New Guinea (PNG). The taipan, Oxyuranus scutellatus, inflicts a large number of bites that, in the absence of antivenom therapy, result in high mortality. Parenteral administration of antivenoms manufactured in Australia is the current treatment of choice for these envenomings. However, the price of these products is high and has increased over the last 25 years; consequently the country can no longer afford all the antivenom it needs. This situation prompted an international collaborative project aimed at generating a new, low-cost antivenom against O. scutellatus for PNG.
METHODOLOGY/PRINCIPAL FINDINGS: A new monospecific equine whole IgG antivenom, obtained by caprylic acid fractionation of plasma, was prepared by immunising horses with the venom of O. scutellatus from PNG. This antivenom was compared with the currently used F(ab')(2) monospecific taipan antivenom manufactured by CSL Limited, Australia. The comparison included physicochemical properties and the preclinical assessment of the neutralisation of lethal neurotoxicity and the myotoxic, coagulant and phospholipase A(2) activities of the venom of O. scutellatus from PNG. The F(ab')(2) antivenom had a higher protein concentration than whole IgG antivenom. Both antivenoms effectively neutralised, and had similar potency, against the lethal neurotoxic effect (both by intraperitoneal and intravenous routes of injection), myotoxicity, and phospholipase A(2) activity of O. scutellatus venom. However, the whole IgG antivenom showed a higher potency than the F(ab')(2) antivenom in the neutralisation of the coagulant activity of O. scutellatus venom from PNG.
CONCLUSIONS/SIGNIFICANCE: The new whole IgG taipan antivenom described in this study compares favourably with the currently used F(ab')(2) antivenom, both in terms of physicochemical characteristics and neutralising potency. Therefore, it should be considered as a promising low-cost candidate for the treatment of envenomings by O. scutellatus in PNG, and is ready to be tested in clinical trials.
|Mariángela Vargas; Alvaro Segura; María Herrera; Mauren Villalta; Ricardo Estrada; Maykel Cerdas; Owen Paiva; Teatulohi Matainaho; Simon D Jensen; Kenneth D Winkel; Guillermo León; José María Gutiérrez; David J Williams|
Related Documents :
|993224 - Poly(glycolic acid) sutures in canine vascular anastomoses.
16405994 - Preparation and characterization of biocompatible polyelectrolyte complex multilayer of...
12711514 - Protein adsorption, fibroblast activity and antibacterial properties of poly(3-hydroxyb...
14985024 - Nanopattern formation on polymer substrate using star-hyperbranched nanospheres.
12067724 - Bax expression protects yeast plasma membrane against ethanol-induced permeabilization.
22244 - Gastric mucosal damage by taurine and glycine conjugates of chenodeoxycholic acid.
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2011-05-17|
|Title: PLoS neglected tropical diseases Volume: 5 ISSN: 1935-2735 ISO Abbreviation: PLoS Negl Trop Dis Publication Date: 2011 May|
|Created Date: 2011-05-25 Completed Date: 2011-09-08 Revised Date: 2013-06-28|
Medline Journal Info:
|Nlm Unique ID: 101291488 Medline TA: PLoS Negl Trop Dis Country: United States|
|Languages: eng Pagination: e1144 Citation Subset: IM|
|Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica.|
|APA/MLA Format Download EndNote Download BibTex|
Antivenins / administration & dosage*, isolation & purification*
Caprylates / chemistry*
Chemical Fractionation / methods*
Immunoglobulin G / administration & dosage*, isolation & purification*
Papua New Guinea
Snake Bites / therapy*
|0/Antivenins; 0/Caprylates; 0/Immunoglobulin G; 124-07-2/octanoic acid|
Journal ID (nlm-ta): PLoS Negl Trop Dis
Journal ID (publisher-id): plos
Journal ID (pmc): plosntds
Publisher: Public Library of Science, San Francisco, USA
Vargas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received Day: 15 Month: 10 Year: 2010
Accepted Day: 27 Month: 2 Year: 2011
collection publication date: Month: 5 Year: 2011
Electronic publication date: Day: 17 Month: 5 Year: 2011
Volume: 5 Issue: 5
E-location ID: e1144
PubMed Id: 21610854
Publisher Id: PNTD-D-10-00078
|Preclinical Evaluation of Caprylic Acid-Fractionated IgG Antivenom for the Treatment of Taipan (Oxyuranus scutellatus) Envenoming in Papua New Guinea Alternate Title:Papuan Taipan Antivenom|
|Simon D. Jensen23|
|Kenneth D. Winkel3|
|José María Gutiérrez1*|
|David J. Williams234|
|David G. Lallooedit1||
1Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica
2School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea
3Australian Venom Research Unit, University of Melbourne, Parkville, Australia
4Nossal Institute for Global Health, University of Melbourne, Parkville, Australia
|Liverpool School of Tropical Medicine, United Kingdom
|Correspondence: * E-mail: email@example.com
Contributed by footnote: Conceived and designed the experiments: M Vargas A Segura M Herrera M Villalta R Estrada KD Winkel G León JM Gutiérrez DJ Williams. Performed the experiments: M Vargas A Segura M Herrera M Villalta R Estrada M Cerdas G León DJ Williams. Analyzed the data: M Vargas A Segura M Herrera M Villalta O Paiva T Matainaho SD Jensen KD Winkel G León JM Gutiérrez DJ Williams. Wrote the paper: O Paiva SD Jensen KD Winkel G León JM Gutiérrez DJ Williams.
Snake bite envenoming represents an important public health hazard in Papua New Guinea (PNG). In the southern lowlands of the country the majority of envenomings are inflicted by the taipan, Oxyuranus scutellatus. The only currently effective treatment for these envenomings is the administration of antivenoms manufactured in Australia. However, the price of these products in PNG is very high and has steadily increased over the last 25 years, leading to chronic antivenom shortages in this country. As a response to this situation, an international partnership between PNG, Australia and Costa Rica was initiated, with the aim of generating a new, low-cost antivenom for the treatment of PNG taipan envenoming. Horses were immunised with the venom of O. scutellatus from PNG and whole IgG was purified from the plasma of these animals by caprylic acid precipitation of non-immunoglobulin proteins. The new antivenom, manufactured by Instituto Clodomiro Picado (Costa Rica), was compared with the currently available F(ab')2 antivenom manufactured by CSL Limited (Australia). Both were effective in the neutralisation of the most relevant toxic effects induced by this venom, although the whole IgG antivenom showed a higher efficacy than the F(ab')2 antivenom in the neutralisation of the coagulant activity.
Envenoming by snake bite is a common medical emergency in Papua New Guinea (PNG) –. Despite incomplete epidemiological data, studies in PNG show that the incidence of snake bite ranges from under five cases per 100,000 people per year in the mountains of Goilala and Hiri (Central Province) and in Madang, to 526–561 cases per 100,000 people per year in the coastal Kairuku lowlands , , . A mortality rate of 7.9 deaths per 100,000 people per year in Central Province was reported for the period 1987–1992 . At Port Moresby General Hospital (PMGH) only envenomed snakebite patients are admitted, and most of these are sent to the Intensive Care Unit (ICU). A study of snakebite admissions to the PMGH ICU between 1992 and 2001 revealed case fatality rates of 8.2% for adults and 14.6% for children . More recently, case fatality rates of 14.5% for adults and 25.9% for children have been reported from the ICU of the same hospital .
Throughout PNG three species of elapid snakes are responsible for nearly all systemic envenomings: Acanthophis laevis (smooth-scaled death adder), Micropechis ikaheka (New Guinea small-eyed snake), and Oxyuranus scutellatus (Papuan taipan). A very small number of envenomings are caused by other Acanthophis species, Pseudechis papuanus (Papuan blacksnake) and Pseudonaja textilis (New Guinea brownsnake) . For many years the Papuan taipan has been regarded as a separate subspecies (Oxyuranus s. canni) to Australian populations (Oxyuranus s. scutellatus). However, recent taxonomic and biogeographical studies have shown that, despite some perceived morphological differences, molecular genetic analysis reveals no significant differentiation between the two populations , . On this basis, O. scutellatus is now considered a single species with both Australian and New Guinean populations. In southern PNG and neighbouring southern Papua, up to 95% of life-threatening snake bites are caused by O. scutellatus (Fig 1). The effects of taipan bite include mild local effects and severe systemic manifestations characterised by coagulopathy with spontaneous systemic haemorrhage, myotoxicity, irreversible flaccid paralysis, acute kidney injury and cardiac disturbances , , –. The neurotoxic manifestations of taipan bite are dominated by the effects of extremely potent, destructive, presynaptic phospholipase A2 toxins, resulting in physical damage to nerve terminals , . Only the early (within 4–6 hours) administration of suitable antivenom can prevent or reduce this presynaptic damage; consequently, when treatment is delayed, severe paralysis occurs, requiring endotracheal intubation and mechanical ventilation until neuromuscular synapses have regenerated , .
Intravenous administration of either taipan monospecific antivenom or polyvalent antivenom prepared in Australia by CSL Limited (CSL) against the venom of Australian O. scutellatus, has been the only effective treatment for envenomings by O. scutellatus in PNG , , . In vitro preincubation studies, using chick biventer cervicis preparations, have shown that this antivenom inhibits the neurotoxic effects of O. scutellatus venom sourced in Indonesian Papua , and clinical observations in PNG have shown its effectiveness in halting spontaneous systemic bleeding and restoring blood coagulability , . Administration of antivenom within four hours of envenoming significantly reduces the incidence of respiratory paralysis . Therefore, a critical issue concerning the management of O. scutellatus envenoming in PNG is the need for rapid access to antivenom, which in turn demands its widespread distribution to hospitals and other health centres. One critical factor limiting the availability of CSL antivenom in PNG is its high price, which has increased more than 800% over the last two decades , , greatly reducing the capacity of the health system to purchase adequate volumes to meet all of the country's needs, leading to chronic shortages. As a consequence, a thriving black market in stolen antivenoms has developed, with private sellers charging as much as US$3,200.00/vial .
An alternative method for manufacturing antivenoms is based on the purification of horse IgG antibodies by fractionation of hyperimmune plasma with caprylic acid –. This simple and inexpensive procedure yields a highly purified whole IgG preparation . Polyspecific antivenoms prepared in this way, at relatively low cost, have been tested in clinical trials in Colombia – and Nigeria , and displayed excellent efficacy and safety. We describe a collaborative effort between teams in Costa Rica, Australia and PNG in the preparation and preclinical evaluation of a monospecific whole IgG antivenom against the venom of O. scutellatus from PNG, and have compared it with the Australian-made CSL taipan antivenom currently in use.
A pool of two grams of venom was obtained from twelve healthy, adult specimens of O. scutellatus collected in PNG's Milne Bay Province and Central Province. These snakes were maintained in a purpose-built serpentarium at the University of PNG, and venom was collected at 21 day intervals. Venom was obtained using Parafilm-covered 50 mL Eppendorf tubes. Samples contaminated by blood were discarded, and all samples were handled using plastic pipettes and tubes. Venom was snap-frozen to −80°C, before being freeze-dried and stored away from light at −20°C. In some experiments, the venom of Australian O. scutellatus obtained from Venom Supplies Pty Limited (Tanunda, South Australia) was used for comparative purposes. In all experiments, lyophilized venom was dissolved in 0.14 M NaCl, 0.04 M phosphate, pH 7.2 (PBS) immediately before use.
Two antivenoms were used in this study:
- (a). Monospecific taipan antivenom manufactured by CSL Limited (CSL), Melbourne, Victoria, Australia (batch B0548-06301; expiry date March 2012).
- (b). Monospecific taipan antivenom manufactured by Instituto Clodomiro Picado (ICP) (batch 4511209 ICP; expiry date November 2012).
CSL monospecific taipan antivenom is prepared from the plasma of horses immunised with the venom of O. scutellatus from Australia. It is manufactured using a protocol based on pepsin digestion and ammonium sulphate fractionation of plasma, and therefore consists of F(ab')2 fragments . ICP monospecific taipan antivenom is raised in horses immunised with the venom of O. scutellatus from PNG. Immunisation was performed in a group of three horses which had not previously been used for antibody production, by using Freund's complete and incomplete adjuvants during the first two injections, respectively, followed by subsequent inoculations of venom dissolved in PBS. All injections were performed by the subcutaneous route in a single anatomical site. When a satisfactory neutralising titre was reached, the animals were bled from the jugular vein, with the blood being collected in 6 L plastic bags containing sodium citrate as anticoagulant. After sedimentation of blood cells, the plasma was separated and the immunoglobulins purified by caprylic acid precipitation (5% final concentration of caprylic acid and one hr stirring) . After filtration in 8 µm pore filter paper, the filtrate was diafiltered and then formulated to contain 7.5 g/L NaCl, 1.6 g/L phenol, pH 7.2 (Table 1). The antivenom solution was sterile filtered using 0.22 µm pore membranes and glass vials were filled with 40 mL of antivenom. The resultant antivenom met all the requirements of the quality control protocol at Instituto Clodomiro Picado.
Total protein concentration was determined by the Biuret test , and electrophoretic analysis was performed by SDS-PAGE, under non-reducing conditions, using an acrylamide concentration of 7.5% . Gels were stained with Coomassie Brilliant Blue R-250. Phenol concentration was determined according to a modification of the method of Lacoste et al. . Caprylic acid concentration was quantified by HPLC according to Herrera et al. . The content of antibody monomers was assessed by FPLC gel filtration in a Superdex 200 10/300 GL column using 0.15 M NaCl, 20 mM Tris, pH 7.5, as eluent. Turbidity was determined using a turbidimeter (La Motte, model 2020, Chestertown, MD), and expressed as nephelometric turbidity units (NTU).
The experimental protocols involving the use of animals in this study were approved by the Institutional Committee for the Care and Use of Laboratory Animals (CICUA) of the University of Costa Rica, and adhere to the International Guiding Principles for Biomedical Research Involving Animals of the Council of International Organizations of Medical Sciences (CIOMS).
Groups of 5 CD-1 mice of both sexes were injected via either the intraperitoneal (i.p.; 16–18 g mice) or the intravenous (i.v.; 18–20 g mice) routes with various amounts of PNG O. scutellatus venom, dissolved in PBS. The volume of injection was 0.5 mL when using the i.p. route and 0.2 mL when using the i.v. route. Deaths occurring during 48 hr were recorded and the Median Lethal Dose (LD50) was estimated by Spearman-Karber .
Groups of 4 CD-1 mice (18–20 g) of both sexes were injected intramuscularly (i.m.), in the right gastrocnemius, with various amounts of venom dissolved in 50 µL PBS. Control mice received 50 µL PBS under otherwise identical conditions. After three hr, mice were bled from the tail and the blood was collected into heparinised capillary tubes. After centrifugation, plasma was collected and the creatine kinase (CK) activity of plasma was quantified by using a commercial kit (CK-Nac, Biokon Diagnostik, Germany). The Minimum Myotoxic Dose (MMD) corresponds to the dose of venom that induced an increment in plasma CK activity corresponding to four times the CK activity of mice injected with PBS .
The method described by Theakston and Reid  and Gené et al.  was followed. Various amounts of venom, dissolved in 100 µL of 0.15 M NaCl, were added to aliquots of 200 µL of human citrated plasma previously incubated at 37°C for 5 min. Experiments were run in quadruplicate. Clotting times were recorded, and the Minimum Coagulant Concentration (MCC) was determined. The MCC corresponds to the concentration of venom that induced plasma clotting in 60 sec. Experiments were performed in both citrated plasma and in citrated plasma to which CaCl2 was added (15 µL of 0.2 M CaCl2 to 200 µL plasma) immediately before addition of the venom, as previously described , .
PLA2 activity was determined titrimetrically, using egg yolk phospholipids as substrates, as previously described . Activity was expressed as µEq fatty acid released per mg protein per min.
A fixed venom dose (“challenge dose”) was pre-incubated with various dilutions of antivenom prior to testing in the corresponding experimental systems, as previously described , . The following challenge doses of venom were used: Lethality (four venom LD50s); coagulant effect (two venom MCCs); myotoxicity (one venom MMD since higher doses were lethal); PLA2 activity (1.5 µg venom). For each effect, the challenge dose of venom was incubated with various dilutions of antivenom, in order to achieve several ratios of mg venom/mL antivenom. Controls included venom incubated with PBS, or 0.15 M NaCl in the case of coagulant effect, instead of antivenom. Incubations were performed for 30 min at 37°C and then aliquots of the mixtures, containing the challenge dose of venom, were tested in the relevant assay systems described above. In the case of coagulant effect, mixtures of venom and antivenom used in the coagulation assay were incubated for no more than 3 min at room temperature (22–25°C) before testing, because incubation of venom for 30 min resulted in a partial loss of coagulant activity (see below). The neutralising ability of antivenoms for lethal and PLA2 activities were expressed as Median Effective Dose (ED50), corresponding to the ratio mg venom/mL antivenom in which the activity of the venom was reduced by 50% . In the case of the coagulant effect, neutralisation was expressed as Effective Dose (ED), corresponding to the ratio mg venom/mL antivenom in which the clotting time is prolonged three times as compared with the clotting time of plasma incubated with venom alone . On the other hand, the estimation of the neutralizing potency against myotoxicity could not follow the method previously described , since the challenge dose used (1 µg) induced a relatively small increment in plasma CK, and higher doses were lethal. Thus, the increment in plasma CK activity in control mice injected with 1 µg of venom alone was only 4 times the value of CK in mice injected with PBS. In these conditions, the value of ED was defined as the ratio mg venom/mL antivenom in which the plasma CK activity was not significantly different from the plasma CK activity of mice injected with PBS alone, i.e. where myotoxicity was completely abrogated.
Pre-incubation of PNG O. scutellatus venom at 37°C for 30 min resulted in a significant loss of coagulant activity. Thus, it was considered that degradation of the procoagulant toxins may be occurring. On this basis, all of the venom activities assessed in this study (LD50, MCC, MMD and PLA2) were determined for venom solutions (a) immediately after dissolution in PBS and (b) after 30 min of incubation at 37°C. Lethality (LD50) by both i.p. and i.v. routes, myotoxicity (MMD) and PLA2 activity were not affected by incubation at 37°C for 30 min. In contrast, the coagulant activity of O. scutellatus venom was reduced upon incubation at 37°C for 30 min. We therefore altered the experimental design of the ED-MCC assay by limiting incubation of venom and antivenom to not more than 3 minutes, in order to avoid the loss of activity associated with incubation.
All descriptive statistic calculations and the Mann Whitney U test used to determine the significance of the differences between the median values of two non-parametric experimental groups in the neutralisation tests were performed using the InStat statistics program.
The physicochemical characteristics of the two antivenoms are summarised in Table 1. The CSL F(ab')2 antivenom had a 3.15 fold higher total protein concentration than ICP whole IgG antivenom. When examined using SDS-PAGE run under non-reducing conditions, the CSL antivenom, manufactured by pepsin digestion and ammonium sulphate fractionation, presented predominant bands in a molecular mass range corresponding to F(ab')2 fragments (Fig 2). In contrast, the whole IgG antivenom fractionated with caprylic acid showed one predominant band of a molecular mass corresponding to IgG monomers. Both antivenoms presented additional minor bands of high molecular mass (in the case of F(ab')2 antivenom) and of 54 and 58 kDa (in the case of IgG antivenom) (Fig 2). Both antivenoms were composed by >90% IgG or F(ab')2 monomers, as judged by gel filtration analysis (Table 1; Fig 3), thus showing a very low protein aggregate content, and had very low turbidity, as assessed both visually and through quantification by nephelometry (Table 1).
The venom of O. scutellatus is highly toxic for CD-1 mice, with LD50 values of 0.04±0.01 µg/mouse (2.3±0.6 µg/kg) and 0.08±0.01 µg/mouse (4.2±0.5 µg/kg) for the i.p. and the i.v. routes, respectively. Lethality was associated with neurotoxicity, as mice showed evidence of limb and respiratory paralysis. Venom also caused myotoxicity in mice, with a MMD of 1 µg per mouse, corresponding to the dose that increased 4 times the plasma CK activity as compared with mice injected with PBS, which had a CK activity of 187±34 U/L. Mice receiving doses higher than 1 µg died before 3 hr. O. scutellatus venom induced coagulation of human plasma, with higher activity in conditions in which CaCl2 was added to citrated plasma before the addition of the venom, as previously reported , . Without addition of calcium, the MCC was 0.76±0.20 µg/mL, whereas when CaCl2 was added to plasma immediately before the venom, the MCC was 0.33±0.13 µg/mL (p<0.05). The PLA2 activity of this venom corresponds to 297±7 µEq fatty acid released per mg protein per min (Table 2).
The two antivenoms were effective at neutralising the four activities tested. No significant differences were observed in the ED50 of either product against the lethal and PLA2 activities of PNG O. scutellatus venom as well as in the ED against myotoxic effect (Table 2). In contrast with lethal, PLA2 and myotoxic activities, there was a significant difference in the value of ED against in vitro coagulant activity of the venom of O. scutellatus from PNG, with the ICP antivenom having 5.2 times and 2.9 times the potency of the CSL antivenom, in experiments performed with calcium and without calcium, respectively (Table 2). In order to ascertain whether this difference is due to antigenic variations between the procoagulants of the venoms from the Australian and Papuan populations of O. scutellatus, the neutralisation of coagulant activity of the venom of Australian O. scutellatus, which is used in the immunizing mixture of the CSL antivenom, was investigated. The MCC of this venom was 1.3±0.6 µg/mL (in experiments where calcium was added to plasma) and 4.1±0.6 µg/mL (without added calcium) (p<0.05). Both antivenoms effectively neutralized this activity, with ICP antivenom showing a higher potency. The EDs in conditions where calcium was added were 10.0±2.5 mg venom neutralized per mL (ICP antivenom) and 4.1±1.4 mg venom/mL antivenom (CSL antivenom) (p<0.05). On the other hand, when calcium was not added to plasma, the values of EDs were 4.9±0.4 mg venom/mL antivenom (ICP antivenom) and 1.5±0.2 mg venom/mL antivenom (CSL antivenom) (p<0.05). When comparing the neutralizing ability of the antivenoms against all effects studied, since the CSL antivenom contains 3.15 times the protein of the ICP antivenom, a lesser amount of antivenom protein is required to achieve neutralisation of the various effects in the case of ICP antivenom.
In the present work, a new, whole IgG monospecific antivenom, obtained by caprylic acid precipitation, was prepared against the venom of Papua New Guinean O. scutellatus, the most medically important venomous snake in the southern halves of both PNG and Indonesian Papua. It was shown that, in standard WHO-endorsed preclinical neutralisation assays, against venom of O. scutellatus from PNG, this new antivenom compares very favourably with the F(ab')2 taipan antivenom currently in use in Australia and PNG.
The venoms of Oxyuranus spp. are among the most toxic ever reported , and our LD50 data on mice confirm the high toxicity of O. scutellatus from PNG. This high toxicity is due predominantly to the presence of a number of neurotoxins, in particular the presynaptic PLA2 trimer, taipoxin (“cannitoxin”) which destroys nerve terminals and also binds to skeletal muscle, leading to myolysis , –. A number of monomeric neurotoxic and myotoxic PLA2, a 52 kDa multimeric voltage-dependent calcium channel blocker, taicatoxin, and a 6.7 kDa post-synaptic α-neurotoxin of 6.7 kDa, α-oxytoxin 1, have also been characterized –. The dominance of destructive presynaptic neurotoxicity in the clinical syndrome of O. scutellatus envenoming has important implications for the treatment of taipan bites, since anticholinesterases do not improve neurotransmission, and more importantly antivenom cannot reverse established neurotoxic manifestations secondary to physical damage to nerve terminals , . Both antivenoms tested in this work are effective in the neutralisation of the lethal effect of Papuan O. scutellatus venom after pre-incubation, thus evidencing their capacity to neutralize the neurotoxins present in this venom.
Disruption of the integrity of skeletal muscle fibre plasma membranes, with rapid impairment of the ability of this membrane to regulate its permeability to ions and macromolecules, is induced by the myotoxic PLA2s, taipoxin and OS2, from the venom of O. scutellatus, –. Both of the tested antivenoms effectively neutralised myotoxicity due to O. scutellatus venom. Since the neurotoxic and myotoxic actions of taipoxin, and similar presynaptically-acting neurotoxins, depend on PLA2 enzymatic activity of these toxins , , the effectiveness of the two antivenoms to neutralize PLA2 activity of O. scutellatus venom is compatible with the neutralisation of these toxic activities.
Coagulopathy occurs in a majority of patients envenomed by O. scutellatus in PNG . This is due to the procoagulant effect of serine proteinases that are potent prothrombin activators –. In agreement with previous studies –, Papuan O. scutellatus venom showed higher in vitro coagulant activity on plasma in conditions where CaCl2 was added to plasma immediately before venom. Regardless of whether the experiments were performed with or without the addition of calcium, ICP antivenom showed a higher potency for the neutralisation of coagulant effect. Interestingly, ICP antivenom was also more effective in the neutralisation of coagulant activity induced by venom from Australian O. scutellatus. These observations suggest that the differences shown by these antivenoms regarding neutralisation of coagulant effect are not likely to be due to antigenic variations in the procoagulant enzymes of these two populations of taipan, but instead to a higher antibody titre against these enzymes of both venoms in ICP antivenom. The basis of this finding remains to be elucidated, but may have to do with differences in the immunization schemes employed in the production of these antivenoms. It is recommended that the analysis of the neutralisation of coagulant activity by Australian venoms by antivenoms should be performed in conditions where calcium is added to citrated plasma before the addition of venom, for reasons previously described –. Clinical studies carried out in PNG demonstrated that CSL taipan antivenom was effective at restoring blood coagulability within 6–12 hr in 93% of patients treated . A future clinical trial will determine whether this difference in the neutralisation of in vitro coagulant activity between these antivenoms will translate into differences in their in vivo clinical efficacy at restoring blood coagulability in envenomed patients.
An unexpected observation during this study was the partial loss of in vitro coagulant activity of the venom upon incubation at 37°C for 30 min. Whether this observation is due to proteolytic degradation or alteration in the quaternary structure of the procoagulant present in this venom, or to a physiologically sub-optimal environment in the in vitro coagulant activity assay remains unknown. Notably, serine proteinase inhibitors had to be used in the isolation of the prothrombin activator  and an apparent in vivo inactivation of the coagulant activity of O. scutellatus venom was described in a monkey model of envenoming . Consequently, we modified the coagulant activity neutralisation protocol in order to avoid the incubation of venom at 37°C for 30 min. Although this modification departs from the conventional way to assess neutralization by antivenoms, i.e. incubation of venom-antivenom mixtures for 30 min, a shorter incubation time, such as the one adapted in this study, also allows a proper testing of neutralization of this activity, since the binding of antibodies to antigens is a very rapid phenomenon. Moreover, both antivenoms were able to neutralize coagulant activity in these circumstances.
There were two important considerations in embarking upon a project that is designed to develop an alternative to a currently available product of established efficacy. These were:
- (a). Antivenom price.
From 1987 to 2007 the cost of CSL polyvalent and taipan antivenoms to the Papua Guinea Department of Health increased drastically, leading to a 40% decline in product availability , . As a consequence, these antivenoms have become increasingly unaffordable to a health system already under enormous stress, leading to chronic antivenom shortages of antivenom and negative patient outcomes . The high prices and relative scarcity have led to a flourishing black market, where stolen antivenoms are resold by private pharmacies and unlicensed wholesalers . We have focused on the need to produce an effective antivenom with a fill volume (40–50 mL) sufficient to neutralize the average “milked” venom yield (120 mg) of healthy, adult O. scutellatus, at the lowest sustainable price, as a means of restoring access to affordable antivenom supplies.
- (b). Local capacity-building.
PNG currently lacks the capacity to produce its own antivenoms or vaccines. Our successful collaborative development of a potent experimental Papuan taipan antivenom demonstrates the relevance of international partnership for approaching public health issues. This project has allowed the development of PNG capacity for venomous snake husbandry, and production of venoms for immunization and quality control. Further efforts will be aimed at strengthening other local capacities in PNG which, in the long term, may lead to the sustainable manufacture of antivenoms in this country.
In conclusion, a new low-cost whole IgG antivenom, obtained by caprylic acid fractionation of horse plasma, was prepared against the venom of O. scutellatus from PNG. The antivenom has a satisfactory preclinical profile in the neutralisation of lethal, PLA2, myotoxic and coagulant effects of O. scutellatus venom, comparable to that of the F(ab')2 antivenom currently in use in PNG. These two antivenoms will be compared further in a randomised, non-inferiority, controlled trial in PNG in order to determine the clinical efficacy and safety profiles of both products.
Mariángela Vargas, Alvaro Segura, María Herrera, Mauren Villalta, Ricardo Estrada, Maykel Cerdas, Guillermo León and José María Gutiérrez work at Instituto Clodomiro Picado, Universidad de Costa Rica, where one of the antivenoms tested in this study was produced.
This study was supported by Vicerrectoría de Investigación, Universidad de Costa Rica (project 741-A9-003); the PNG Office of Higher Education, CTP Limited (Milne Bay Estates), and the Australian Venom Research Unit (University of Melbourne), which is funded by the Australian Government Department of Health and Ageing, the Australia Pacific Science Foundation and Snowy Nominees. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The authors thank the staff of the Industrial Division of Instituto Clodomiro Picado for their support in the preparation of the antivenom, and Professor David A. Warrell for critical revision of the manuscript and for valuable suggestions and insights. We also thank Jasper Gabugabu for his excellent husbandry of our captive Papuan taipans; Mark O'Shea, Wolfgang and Catharine Wüster, Timothy Bosalidi, Ben Bal and Ronelle Welton for assisting in the capture of taipan snakes under difficult, dangerous field conditions; the University of PNG (Professor Ross Hynes, Professor Sir Isi Kevau and Professor Mathias Sapuri) for infrastructure resources and support; past and present PNG Ministers for Health & HIV/AIDS, the Hon. Sir Peter Barter MP., and the Hon. Sasa Zibe MP.; past and present Health Secretaries, Dr Nicholas Mann and Dr Clement Malau; past Deputy-Health Secretary Dr Timothy Pyakalyia; and especially the late Sir Philip Willmott-Sharp and Lady Brenda Willmott-Sharp who have extensively supported work by one of us (DJW) in PNG for many years.
|1.||Currie BJ,Sutherland SK,Hudson BJ,Smith AM. Year: 1991An epidemiological study of snake bite envenomation in Papua New Guinea.Med J Aust1542661681994203|
|2.||Lalloo DG,Trevett AJ,Korinhona A,Nwokolo N,Laurenson IF,et al. Year: 1995Snake bites by the Papuan taipan (Oxyuranus scutellatus canni): paralysis, hemostatic and electrocardiographic abnormalities, and effects of antivenom.Am J Trop Med Hyg525255317611559|
|3.||Williams D. Year: 2005Snakebite in Papua New Guinea.Williams DJ,Jensen SD,Nimorakiotakis B,Winkel KD532 Venomous Bites and Stings in Papua New Guinea: A Treatment Guide for Health Workers and Doctors. Melbourne: University of Melbourne.|
|4.||Williams D,Bal B. Year: 2003Papuan taipan Oxyuranus scutellatus canni envenomation in rural Papua New Guinea.Annals of the ACTM469|
|5.||McGain F,Limbo A,Williams DJ,Didei G,Winkel KD. Year: 2004Snakebite mortality at Port Moresby General Hospital, Papua New Guinea, 1992-2001.Med J Aust18168769115588214|
|6.||Wüster W,Dumbrell A,Hay C,Pook CE,Williams DJ,Fry BG. Year: 2005Snakes across the Strait: Phylogeographic relationships in three genera of Australasian snakes (Serpentes: Elapidae: Acanthophis, Oxyuranus and Pseudechis).Mol Phylog Evol34114|
|7.||Doughty P,Maryan B,Donnellan SC,Hutchinson MN. Year: 2007A new species of taipan (Elapidae: Oxyuranus) from central Australia.Zootaxa14224558|
|8.||Lalloo DG,Trevett AJ,Owens D,Minei J,Naraqi S,et al. Year: 1995Coagulopathy following bites by the Papuan taipan (Oxyuranus scutellatus canni).Blood Coagul Fibrinolysis665727540879|
|9.||Lalloo DG,Trevett AJ,Nwokolo N,Laurenson IF,Naraqi S,et al. Year: 1997Electrocardiographic abnormalities in patients bitten by taipans (Oxyuranus scutellatus canni) and other elapid snakes in Papua New Guinea.Trans Royal Soc Trop Med Hyg915356|
|10.||Trevett AJ,Lalloo DG,Nwokolo NC,Naraqi S,Kevau IH,et al. Year: 1995Electrophysiological findings in patients envenomed following the bite of a Papuan taipan (Oxyuranus scutellatus canni).Trans Royal Soc Trop Med Hyg89415417|
|11.||Harris JB,Grubb BD,Maltin CA,Dixon R. Year: 2000The neurotoxicity of the venom phospholipases A2, notexin and taipoxin.Exp Neurol16151752610686073|
|12.||Montecucco C,Gutiérrez JM,Lomonte B. Year: 2008Cellular pathology induced by snake venom phospholipase A2 myotoxins and neurotoxins: common aspects of their mechanisms of action.Cell Mol Life Sci652897291218563294|
|13.||Connolly S,Trevett AJ,Nwokolo NC,Lalloo DG,Naraqi S,et al. Year: 1995Neuromuscular effects of Papuan Taipan snake venom.Ann Neurol389169208526464|
|14.||Trevett AJ,Lalloo DG,Nwokolo NC,Naraqi S,Kevau IH,et al. Year: 1995The efficacy of antivenom in the treatment of bites by the Papuan taipan (Oxyuranus scutellatus canni).Trans Royal Soc Trop Med Hyg89322325|
|15.||Crachi MT,Hammer LW,Hodgson WC. Year: 1999The effects of antivenom on the in vitro neurotoxicity of venoms from the taipans Oxyuranus scutellatus, Oxyuranus microlepidotus and Oxyuranus scutellatus canni.Toxicon371771177810519654|
|16.||Williams DJ. Year: 2005Snakebite in southern Papua New Guinea. Postgraduate Dissertation. School of Public Health & Tropical Medicine, James Cook University.|
|17.||Warrell DA. Year: 2008102397399 Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product – ‘What's in a name?’ Trans Royal Soc Trop Med Hyg.|
|18.||dos Santos MC,D'Imperio-Lima MR,Furtado GC,Colletto GM,Kipnis TL,et al. Year: 1989Purification of F(ab')2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield.Toxicon272973032728022|
|19.||Rojas G,Jiménez JM,Gutiérrez JM. Year: 1994Caprylic acid fractionation of hyperimmune horse plasma: Description of a simple procedure for antivenom production.Toxicon323513638016856|
|20.||Raweerith R,Ratanabanangkoon K. Year: 2003Fractionation of equine antivenom using caprylic acid precipitation in combination with cationic ion-exchange chromatography.J Immunol Methods282637214604541|
|21.||World Health OrganizationYear: 2010 Guidelines for the Production, Control and Regulation of Antivenom Immunoglobulins. World Health Organization, Geneva (www.who.int/bloodproducts/snakeantivenoms).|
|22.||Otero-Patiño R,Cardoso J L C,Higashi H G,Núñez V,Díaz A,et al. Year: 1998A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for Bothrops snake bites in Urabá, Colombia.Am J Trop Med Hyg581831899580075|
|23.||Otero R,Gutiérrez JM,Rojas G,Núñez V,Díaz A,et al. Year: 1999A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia. Correlation between safety and biochemical characteristics of antivenoms.Toxicon3789590810340829|
|24.||Otero R,León G,Gutiérrez JM,Rojas G,Toro MF,et al. Year: 2006Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without β-propiolactone, in the treatment of Bothrops asper bites in Colombia.Trans R Soc Trop Med Hyg1001173118216698053|
|25.||Abubakar IS,Abubakar SB,Habib AG,Nasidi A,Durfa N,et al. Year: 2010Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria.PLoS Negl Trop Dis4e76720668549|
|26.||Meier J. Year: 1995Commercially available antivenoms (“hyperimmune sera”, “antivenins”, “antisera”) for antivenom therapy.Meier J,White J689721 Handbook of Clinical Toxicology of Animal Venoms and Poisons. Boca Raton: CRC Press.|
|27.||Schosinsky K,Vargas M,Vinocour G,González OM,Brilla E,et al. Year: 1983Manual de Técnicas de Laboratorio. Química Clínica. Universidad de Costa Rica, San José.|
|28.||Laemmli UK. Year: 1970Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature2276806855432063|
|29.||Lacoste RJ,Venable SH,Stone JC. Year: 1959Modified 4-aminoantipyrine colorimetric method for phenols. Application to an acrylic monomer.Anal Chem3112461249|
|30.||Herrera M,Meneses F,Gutiérrez JM,León G. Year: 2009Development and validation of a reverse phase HPLC method for the determination of caprylic acid in formulations of therapeutic immunoglobulins and its application to antivenom production.Biologicals3723023419375941|
|31.||World Health OrganizationYear: 1981Progress in the Characterization of Venoms and Standardization of Antivenoms. WHO Offset Publication No. 58. World Health Organization, Geneva.|
|32.||Rojas E,Quesada L,Arce V,Lomonte B,Rojas G,et al. Year: 2005Neutralization of tour Peruvian Bothrops sp snake venoms by polyvalent antivenoms produced in Perú and Costa Rica: preclinical assessment.Acta Trop93859515589801|
|33.||Theakston RDG,Reid HA. Year: 1983Development of simple standard assay procedures for the characterization of snake venoms.Bull World Health Org619499566609011|
|34.||Gené JA,Roy A,Rojas G,Gutiérrez JM,Cerdas L. Year: 1989Comparative study on coagulant, defibrinating, fibrinolytic and fibrinogenolytic activities of Costa Rican crotaline snake venoms and their neutralization by a polyvalent antivenom.Toxicon278418482781583|
|35.||Isbister GK,Woods D,Alley S,O'Leary MA,Seldon M,et al. Year: 2010Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom.Toxicon56758520338189|
|36.||O'Leary MA,Isbister GK. Year: 2010A turbidimetric assay for the measurement of clotting times of procoagulant venoms in plasma.J Pharmacol Toxicol Meth612731|
|37.||Gutiérrez JM,Lomonte B,Chaves F,Moreno E,Cerdas L. Year: 1986Pharmacological activities of a toxic phospholipase A isolated from the venom of the snake Bothrops asper.Comp Biochem Physiol84C159164|
|38.||Gutiérrez JM,Rojas G,Lomonte B,Gené JA,Chaves F,et al. Year: 1990Standardization of assays for testing the neutralizing ability of antivenoms.Toxicon28112711292264065|
|39.||Broad AJ,Sutherland SK,Coulter AR. Year: 1979The lethality in mice of dangerous Australian and other snake venom.Toxicon17661664524395|
|40.||Fohlman J,Eaker D,Karlsson E,Thesleff S. Year: 1976Taipoxin, an extremely potent presynaptic neurotoxin from the venom of the Australian snake taipan (Oxyuranus s. scutellatus). Isolation, characterization, quaternary structure and pharmacological properties.Eur J Biochem68457469976268|
|41.||Kuruppu S,Reeve S,Banerjee Y,Kini RM,Smith I,et al. Year: 2005Isolation and pharmacological characterization of cannitoxin, a presynaptic neurotoxin from the venom of the Papuan taipan (Oxyuranus scutellatus canni).J Pharmacol Exp Ther3151196120216135698|
|42.||Harris JB,Maltin CA. Year: 1982Myotoxic activity of the crude venom and the principal neurotoxin, taipoxin, of the Australian taipan, Oxyuranus scutellatus.Br J Pharmacol7661757082907|
|43.||Lambeau G,Barhanin J,Schweitz H,Qar J,Lazdunski M. Year: 1989Identification and properties of very high affinity brain membrane-binding sites for a neurotoxic phospholipase from the taipan venom.J Biol Chem 264: 11,503-11,510|
|44.||Lambeau G,Lazdunski M,Barhanin J. Year: 1991Properties of receptors for neurotoxic phospholipases A2 in different tissues.Neurochem Res166516581791912|
|45.||Brown AM,Yatani A,Lacerda AE,Gurrola GB,Possani LD. Year: 1987Neurotoxins that act selectively on voltage-dependent cardiac calcium channels.Circ Res611619|
|46.||Possani LD,Martin BM,Yatani A,Mochca-Morales J,Zamudio FZ,et al. Year: 1992Isolation and physiological characterization of taicatoxin, a complex toxin with specific effects on calcium channels.Toxicon30134313641485334|
|47.||Kornhauser R,Hart AJ,Reeve S,Smith AI,Fry BG,et al. Year: 2010Variations in the pharmacological profile of post-synaptic neurotoxins isolated from the venoms of the Papuan (Oxyuranus scutellatus canni) and coastal (Oxyuranus scutellatus scutellatus) taipans.Neurotoxicology3123924320036687|
|48.||Trevett AJ,Lalloo DG,Nwokolo NC,Naraqi S,Kevau IH,et al. Year: 1995Failure of 3,4 diaminopyridine and edrophonium to produce significant clinical benefit in neurotoxicity following the bite of Papuan taipan (Oxyuranus scutellatus canni).Trans Royal Soc Trop Med Hyg89444446|
|49.||Gutiérrez JM,Ownby CL. Year: 2003Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity.Toxicon4291593115019491|
|50.||Roault M,Rash LD,Escoubas P,Boilard E,Bollinger J,et al. Year: 2006Neurotoxicity and other pharmacological activities of the snake venom phospholipase A2 OS2: the N-terminal region is more important than enzymatic activity.Biochemistry455800581616669624|
|51.||Harris JB. Year: 1991Phospholipases in snake venoms and their effects on nerve and muscle.Harvey ALNew YorkPergamon Press91129 Snake Toxins..|
|52.||Paoli M,Rigoni M,Koster G,Rossetto O,Montecucco C,et al. Year: 2009Mass spectrometry analysis of the phospholipase A2 activity of snake pre-synaptic neurotoxins in cultured neurons.J Neurochem11173774419712054|
|53.||Walker FJ,Owen WG,Esmon CT. Year: 1980Characterization of the prothrombin activator from the venom of Oxyuranus scutellatus scutellatus (taipan venom).Biochemistry19102010236986908|
|54.||Speijer H,Govers-Riemslag JWP,Zwaal RFA,Rosing J. Year: 1986Prothrombin activation by an activator from the venom of Oxyuranus scutellatus (taipan snake).J Biol Chem26113258132673531198|
|55.||Kini RM. Year: 2005Serine proteases affecting blood coagulation and fibrinolysis from snake venoms.Pathophysiol Haemost Thromb3420020416707928|
|56.||Sutherland SK,Campbell DG,Stubbs AE. Year: 1981A study of the major Australian snake venoms in the monkey (Macaca fascicularis). II. Myolytic and haematological effects of venoms.Pathology137057157335377|
|57.||Currie B,Vince J,Naraqi S. Year: 1988Snake bite in Papua New Guinea.PNG Med J31195198|
|58.||Williams DJ. Year: 2007Proposal for establishment of a national antivenom unit: Submission to the Government of the Independent State of Papua New Guinea. Australian Venom Research Unit, University of Melbourne.|
Table 1 Physicochemical characteristics of antivenoms.
|Characteristic||ICP IgG antivenom||CSL F(ab')2 antivenom|
|Caprylic acid (mg/L)||31±1||−|
|Monomer content (%)a||93±1.0||93±0.4|
aMonomer content is expressed as the percentage of antivenom protein present as either IgG or F(ab')2 monomers, as analyzed by gel filtration (see Materials and Methods).
bTurbidity is expressed as Nephelometric Turbidity Units (see details in Materials and Methods).
Table 2 Toxic activities of O. scutellatus venom and neutralisation by antivenoms.
|Effect||Activity||ICP IgG antivenom (Batch 4511209 ICP)||CSL F(ab')2 antivenom (Batch B0548-06301)|
|mg Venom/mL Antivenomd||Neutralising Unitse||mg Venom/mL Antivenomd||Neutralising Unitse|
|Lethality (i.p.) (LD50)a||0.04±0.01 µg||4.50 (3.18–6.41)||18,000||5.65 (3.89–8.77)||18,645|
|Lethality (i.v.) (LD50)a||0.08±0.01 µg||4.35 (3.05–5.29)||17,400||5.81 (4.08–7.04)||19,173|
|Coagulant (MCC)b without calcium||0.76±0.20 µg/mL||2.43±0.29*||0.84±0.04*|
|Coagulant (MCC) with calcium||0.33±0.13 µg/mL||2.37±0.08*||0.45±0.17*|
|Myotoxic (MMD)c||1 µg||4.0||4.0|
|PLA2 ( µEq/mg/min)||297±7||1.47±0.29||1.10±0.38|
aLethal activity was determined for the i.p. and i.v. routes in CD-1 mice. Median Lethal Dose (LD50) is expressed as µg venom/mouse (mean ± S.D)
bCoagulant activity, expressed as the Minimum Coagulant Concentration (MCC), either in citrated plasma or in citrated plasma to which CaCl2 was added immediately before the test. Results are the mean ± S.D.
cMyotoxic activity, expressed as the Minimum Myotoxic Dose (MMD).
dNeutralisation is expressed as either ED50 (lethality and PLA2) or ED (coagulant and myotoxic effects) (see Materials and Methods for details). Results are presented as mg venom neutralised per mL antivenom. For lethality, the 95% confidence limits are included in parenthesis. For the other effects, results are presented as mean ± S.D. (n = 4–6). Challenge doses of venom correspond to 4 LD50s (lethality), 2 MCCs (coagulant), 1 MMD (myotoxicity), and 1.5 µg venom (PLA2 activity).
eCSL taipan antivenom is labelled as containing at least 12,000 Neutralising Units of antivenom, where 1 Unit = 0.01 mg venom neutralised (i.e.: 12,000 units neutralises 120 mg venom). Actual neutralising unit values for each antivenom are given here for comparison and are calculated from fill volumes of each product.
nt108*: p<0.05 when the two antivenoms are compared.
Previous Document: Orientia tsutsugamushi stimulates an original gene expression program in monocytes: relationship wit...
Next Document: Schistosoma haematobium treatment in 1-5 year old children: safety and efficacy of the antihelminthi...